Gilead Sciences, Inc.
NEWS
This is a market like the world has never seen.
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County.
These stocks have been given a Strong Buy or Buy rating by 80% or more brokers.
Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years.
These prominent drug developers look to be enticing buys this month.
Thanks to the Republican tax legislation, pharmaceutical stocks are set to continue their heady northward trajectory in 2018.
Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018.
You don’t have to be a dairy farmer to like a cash cow.
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.
JOBS
IN THE PRESS